期刊
JOURNAL OF THORACIC ONCOLOGY
卷 11, 期 5, 页码 E59-E62出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtho.2015.12.102
关键词
Mesenchymal-epithelial transition; Lung cancer; Copy number gain; MET/CEP7 ratio; Crizotinib
资金
- National Natural Science Foundation of China [81402561]
MMNG HOS Transforming gene (MET) is an important driver gene in non-small cell lung cancer. Yet, MET-relevant biomarkers predictive of clinical response to MET inhibitors remain elusive. Limited studies have indicated some possibly effective biomarkers, including amplification with a high-level MET/centromere probe of chromosome 7 (CEP7) ratio, MET exon 14 (METex14) splicing mutations, and MET over expression. MET copy number gain (MCNG) is an independent negative prognostic factor in non-small cell lung cancer. Therefore, there remains a lack of clinical evidence regarding whether MCNG is a biomarker predictive of response to MET inhibitors. Here we report a patient with lung adenocarcinoma with MCNG but without a high-level MET/CEP7 ratio or METex14 splicing mutations who achieved a rapid response to crizotinib, indicating that MCNG may be an independent predictive biomarker for response to MET inhibitors. (C) 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据